Philipp T Meyer

List of Publications by Year
in descending order

		101543	76900
125 papers	6,248 citations	36 h-index	74 g-index
127 all docs	127 docs citations	127 times ranked	8017 citing authors

#	Article	IF	Citations
1	Novel Neuronal Autoantibodies in Huntington's Disease. Biological Psychiatry, 2022, 91, e21-e23.	1.3	6
2	Hemodynamic evaluation of patients with Moyamoya Angiopathy: comparison of resting-state fMRI to breath-hold fMRI and [15O]water PET. Neuroradiology, 2022, 64, 553-563.	2.2	8
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
4	Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms. Brain, 2022, 145, 3203-3213.	7.6	25
5	Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. Journal of Nuclear Medicine, 2022, 63, 971-980.	5.0	41
6	Neural activity of the auditory cortex predicts speech recognition of patients with asymmetric hearing loss after cochlear implantation. Scientific Reports, 2022, 12, 8068.	3.3	1
7	Principal-Component Analysis–Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. Journal of Nuclear Medicine, 2021, 62, 855-860.	5.0	6
8	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828.	5.0	32
9	Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1445-1459.	6.4	12
10	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology, 2021, 96, e1358-e1368.	1.1	11
11	Brain activation patterns during visuomotor adaptation in motor experts and novices: An FDG PET study with unrestricted movements. Journal of Neuroscience Methods, 2021, 350, 109061.	2.5	5
12	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research, 2021, 81, 2234-2245.	0.9	11
13	Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. Journal of Nuclear Medicine, 2021, 62, jnumed.121.262128.	5.0	108
14	99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. EJNMMI Research, 2021, 11, 22.	2.5	12
15	Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain, 2021, 144, 1263-1276.	7.6	245
16	Reply: From early limbic inflammation to long COVID sequelae. Brain, 2021, 144, e66-e66.	7.6	3
17	PET/CT background noise and its effect on speech recognition. Scientific Reports, 2021, 11, 22065.	3.3	2
18	Gastrin-Releasing Peptide Receptor Antagonist [68Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer. Cancers, 2021, 13, 6106.	3.7	10

#	Article	IF	Citations
19	Predictive Value of ^{18}F-Florbetapir and ^{18}F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. Journal of Nuclear Medicine, 2020, 61, 597-603.	5.0	30
20	^{18}F-FDG PET Imaging of the Inferior Colliculus in Asymmetric Hearing Loss. Journal of Nuclear Medicine, 2020, 61, 418-422.	5.0	25
21	Neuropsychological impairment in adults with moyamoya angiopathy: preoperative assessment and correlation to MRI and H215O PET. Neurosurgical Review, 2020, 43, 1615-1622.	2.4	23
22	[123I]FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: AÂData-Driven Analysis. Journal of Parkinson's Disease, 2020, 10, 1457-1465.	2.8	2
23	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. Npj Parkinson's Disease, 2020, 6, 39.	5.3	8
24	Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome. Clinical Nuclear Medicine, 2020, 45, 283-287.	1.3	14
25	Association between gastrin-releasing peptide receptor expression as assessed with [68Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer. Nuclear Medicine and Biology, 2020, 86-87, 37-43.	0.6	5
26	Psychiatric Manifestation of Anti-LGI1 Encephalitis. Brain Sciences, 2020, 10, 375.	2.3	12
27	Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies. Brain Sciences, 2020, 10, 399.	2.3	7
28	Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. Clinical Nuclear Medicine, 2020, 45, 519-524.	1.3	9
29	Probable Autoimmune Catatonia With Antibodies Against Cilia on Hippocampal Granule Cells and Highly Suspicious Cerebral FDG-Positron Emission Tomography Findings. Biological Psychiatry, 2020, 87, e29-e31.	1.3	15
30	Deep Brain Stimulation of the Medial Forebrain Bundle in a Rodent Model of Depression: Exploring Dopaminergic Mechanisms with Raclopride and Micro-PET. Stereotactic and Functional Neurosurgery, 2020, 98, 8-20.	1.5	15
31	Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. EJNMMI Research, 2020, 10, 17.	2.5	20
32	Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to [123I]FP-CIT SPECT and [18F]FDG PET. Journal of Alzheimer's Disease, 2020, 78, 1721-1729.	2.6	2
33	Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 312-323.	6.4	20
34	Outcome After PSMA PET/CTâ€"Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 227-233.	5.0	61
35	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.6	42
36	Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. EJNMMI Research, 2019, 9, 37.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Psychiatric Presentation of Anti-NMDA Receptor Encephalitis. Frontiers in Neurology, 2019, 10, 1086.	2.4	31
38	Detection Rate of ^{18}F-Choline PET/CT and ^{68}Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. Journal of Nuclear Medicine, 2019, 60, 971-977.	5.0	35
39	[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals, 2019, 12, 18.	3.8	41
40	Limits for Reduction of Acquisition Time and Administered Activity in ^{18}F-FDG PET Studies of Alzheimer Dementia and Frontotemporal Dementia. Journal of Nuclear Medicine, 2019, 60, 1764-1770.	5.0	12
41	Accuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology. Nuclear Medicine and Biology, 2019, 70, 32-38.	0.6	18
42	Hypercapnic BOLD MRI compared to H215O PET/CT for the hemodynamic evaluation of patients with Moyamoya Disease. NeuroImage: Clinical, 2019, 22, 101713.	2.7	28
43	Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. Current Opinion in Neurology, 2019, 32, 548-556.	3.6	8
44	Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-l-Tyrosine PET. Clinical Nuclear Medicine, 2019, 44, 695-701.	1.3	14
45	Principal Components Analysis of Brain Metabolism Predicts Development of Alzheimer Dementia. Journal of Nuclear Medicine, 2019, 60, 837-843.	5.0	50
46	Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes. Deutsches A&#x0308;rzteblatt International, 2019, 116, 747-754.	0.9	27
47	Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study. Journal of Neural Transmission, 2018, 125, 995-1005.	2.8	8
48	^{68}Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine, 2018, 59, 1406-1411.	5.0	106
49	Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1442-1448.	6.4	14
50	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology, 2018, 14, 751-769.	2.4	7
51	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
52	Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiation Oncology, 2018, 13, 159.	2.7	26
53	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
54	Voxel-wise deviations from healthy aging for the detection of region-specific atrophy. NeuroImage: Clinical, 2018, 20, 851-860.	2.7	18

#	Article	IF	Citations
55	Estimation of Severity of Moyamoya Disease with [15O]Water-Positron Emission Tomography Compared with Magnetic Resonance Imaging and Angiography. World Neurosurgery, 2018, 117, e75-e81.	1.3	11
56	Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2062-2070.	6.4	13
57	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiation Oncology, 2018, 13, 65.	2.7	26
58	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiation Oncology, 2018, 13, 81.	2.7	53
59	Regional neuronal activity in patients with relapsing remitting multiple sclerosis. Acta Neurologica Scandinavica, 2018, 138, 466-474.	2.1	10
60	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiotherapy and Oncology, 2017, 123, 472-477.	0.6	50
61	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1463-1472.	6.4	51
62	Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. Nuclear Medicine and Biology, 2017, 45, 22-29.	0.6	14
63	^{18}F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. Journal of Nuclear Medicine, 2017, 58, 1888-1898.	5.0	139
64	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by ^{18}F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. Journal of Nuclear Medicine, 2017, 58, 129-137.	5.0	45
65	Comparison of ^{68}Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	10.0	135
66	Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics, 2017, 7, 1770-1780.	10.0	123
67	Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake. PLoS ONE, 2017, 12, e0170435.	2.5	24
68	Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist ^{68}Ga-RM2 And PET. Theranostics, 2016, 6, 1641-1650.	10.0	90
69	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) â€" protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.	2.6	62
70	Staphylococcus aureus bacteremia with iliac artery endarteritis in a patient receiving ustekinumab. BMC Infectious Diseases, 2016, 16, 586.	2.9	8
71	Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers. Journal of Nuclear Medicine, 2016, 57, 1282-1288.	5.0	20
72	Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. Acta OncolÃ³gica, 2016, 55, 1299-1304.	1.8	28

#	ARTICLE	IF	CITATIONS
73	Metabolic patterns associated with survival in PSP/CBS: An 18FDG PET voxel-based analysis. Basal Ganglia, 2016, 6, 45-51.	0.3	0
74	MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 889-897.	6.4	68
75	Immuno-PET Imaging of CD30-Positive Lymphoma Using [89]Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody. Journal of Nuclear Medicine, 2016, 57, 96-102.	5.0	33
76	Characterization of [^{123}I]FP–CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative *in vitro* autoradiography. Synapse, 2015, 69, 497-504.	1.2	9
77	(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. PLoS ONE, 2015, 10, e0145755.	2.5	46
78	Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. Molecular Pharmaceutics, 2015, 12, 2781-2790.	4.6	43
79	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
80	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
81	Role of Semiquantitative Assessment of Regional Binding Potential in 123I-FP-CIT SPECT for the Differentiation of Frontotemporal Dementia, Dementia With Lewy Bodies, and Alzheimer's Dementia. Clinical Nuclear Medicine, 2015, 40, e27-e33.	1.3	16
82	^{18}F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism. Journal of Nuclear Medicine, 2015, 56, 1541-1546.	5.0	29
83	Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. Brain, 2015, 138, 3089-3099.	7.6	72
84	Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 278-86.	1.0	6
85	Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 2014, 4, 412-419.	10.0	127
86	Update on SPECT and PET in parkinsonism – part 1. Current Opinion in Neurology, 2014, 27, 390-397.	3.6	23
87	A disease-specific metabolic brain network associated with corticobasal degeneration. Brain, 2014, 137, 3036-3046.	7.6	103
88	Estrogen Intake and Copper Depositions: Implications for Alzheimer's Disease. Case Reports in Neurology, 2014, 6, 181-187.	0.7	18
89	Update on SPECT and PET in parkinsonism – part 2. Current Opinion in Neurology, 2014, 27, 398-404.	3.6	14
90	Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study. Parkinsonism and Related Disorders, 2014, 20, 898-906.	2.2	24

#	ARTICLE	IF	CITATIONS
91	Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. Journal of Neurology, 2013, 260, 2744-2753.	3.6	186
92	Neural correlates of cognitive dysfunction in Lewy body diseases and tauopathies: Combined assessment with FDG-PET and the CERAD test battery. Brain and Language, 2013, 127, 307-314.	1.6	6
93	Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease. Behavioural Brain Research, 2013, 239, 15-26.	2.2	23
94	123I-Iodobenzamide SPECT Is Not an Independent Predictor of Dopaminergic Responsiveness in Patients with Suspected Atypical Parkinsonian Syndromes. Journal of Nuclear Medicine, 2013, 54, 2081-2086.	5.0	8
95	Amyloid-β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia. Journal of Nuclear Medicine, 2013, 54, 1909-1914.	5.0	21
96	Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine. Journal of Nuclear Medicine, 2012, 53, 1558-1564.	5.0	3
97	Image Quality and Data Quantification in Dopamine Transporter SPECT. Clinical Nuclear Medicine, 2012, 37, 866-871.	1.3	23
98	Caffeine Occupancy of Human Cerebral A_1 Adenosine Receptors: In Vivo Quantification with ^{18}F-CPFPX and PET. Journal of Nuclear Medicine, 2012, 53, 1723-1729.	5.0	74
99	[^{18}F]FDG-PET is superior to [^{123}I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology, 2012, 79, 1314-1322.	1.1	165
100	[18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. Nuclear Medicine and Biology, 2012, 39, 1077-1080.	0.6	11
101	Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and ^{11}C-Labeled Pittsburgh Compound B. Journal of Nuclear Medicine, 2011, 52, 393-400.	5.0	97
102	Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. NeuroImage, 2010, 50, 984-993.	4.2	21
103	Positron Emission Tomography Imaging in Human Immunodeficiency Virus-1-Associated Neurocognitive Disorders. Clinical Nuclear Medicine, 2009, 34, 496-499.	1.3	1
104	Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 589-597.	6.4	28
105	Cerebral kinetics of the dopamine D2 receptor ligand [123I]IBZM in mice. Nuclear Medicine and Biology, 2008, 35, 467-473.	0.6	10
106	Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice. Nuclear Medicine and Biology, 2008, 35, 543-548.	0.6	10
107	Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach. NeuroImage, 2008, 42, 548-558.	4.2	17
108	Sleep Deprivation Increases A1 Adenosine Receptor Binding in the Human Brain: A Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 2410-2415.	3.6	169

#	Article	IF	Citations
109	Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. Neurobiology of Aging, 2007, 28, 1914-1924.	3.1	63
110	Testâ€"retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1061-1070.	6.4	20
111	A1 adenosine receptor PET using [18F]CPFPX: Displacement studies in humans. NeuroImage, 2006, 32, 1100-1105.	4.2	20
112	Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nuclear Medicine and Biology, 2006, 33, 891-898.	0.6	27
113	Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 948-954.	6.4	51
114	18F-CPFPX PET: on the generation of parametric images and the effect of scan duration. Journal of Nuclear Medicine, 2006, 47, 200-7.	5.0	10
115	Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: Analyses based on venous blood sampling. Synapse, 2005, 55, 212-223.	1.2	12
116	Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. NeuroImage, 2005, 24, 1192-1204.	4.2	25
117	Impact of sleep deprivation on cerebral A1 adenosine receptor (A1AR) density: A PET study. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S316-S316.	4.3	0
118	Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 323-333.	4.3	33
119	Preoperative mapping of cortical motor function: prospective comparison of functional magnetic resonance imaging and [15O]-H2O-positron emission tomography in the same co-ordinate system. Nuclear Medicine Communications, 2004, 25, 987-997.	1.1	20
120	Preoperative mapping of cortical language areas in adult brain tumour patients using PET and individual non-normalised SPM analyses. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 951-960.	6.4	62
121	In vivo imaging of rat brain A 1 adenosine receptor occupancy by caffeine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1440-1440.	6.4	10
122	In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage, 2003, 19, 1760-1769.	4.2	84
123	Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. Journal of Nuclear Medicine, 2003, 44, 839-45.	5.0	27
124	Preoperative brain mapping using [15 O]water activation PET provides evidence on altered language networks in an adult brain tumour patient. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1705-1705.	6.4	1
125	Localisation of motor areas in brain tumour patients: a comparison of preoperative [18F]FDG-PET and intraoperative cortical electrostimulation. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1394-1403.	2.1	39